Literature DB >> 22907255

Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer.

Yung-Chang Lin1, Jayashri Mahalingam, Jy-Ming Chiang, Po-Jung Su, Yu-Yi Chu, Hsin-Yi Lai, Jian-He Fang, Ching-Tai Huang, Cheng-Tang Chiu, Chun-Yen Lin.   

Abstract

Activated T regulatory (T(reg)) cells are potent suppressors that mediate immune tolerance. We investigated the relationship between activated T(reg) cells and the progression of human colon cancer. We designed a cross-sectional study of CD4(+) Foxp3(+) T cells from peripheral blood, primary tumor and nontumor colon tissue of 42 patients with colon cancer and correlated the percentages of different subgroups of T(reg) cells with colon cancer stage. The phenotypes, cytokine-release patterns and suppression ability of these T(reg) cells were analyzed. We found that T(reg) cells increased significantly in both peripheral blood and cancer tissue. In addition, the T(reg) cells expressed significantly lower levels of CCR7, CD62L and CD45RA in comparison to normal volunteers. Further dividing T(reg) cells into subgroups based on Foxp3 and CD45RA expression revealed that both activated T(reg) cells (Foxp3(hi) CD45RA(-)) and nonsuppressive T(reg) cells (Foxp3(lo) CD45RA(-)), but not resting T(reg) cells (Foxp3(low) CD45RA(+)), increased in the peripheral blood and cancer tissue of patients with colon cancer. Only the activated T(reg) cells expressed significantly higher levels of tumor necrosis factor receptor 2 and cytotoxic T-cell antigen-4. Activated T(reg) cells, however, secreted significantly lower levels of effector cytokines (interleukin-2, tumor necrosis factor-α and interferon-γ) than did resting T(reg) cells and nonsuppressive cells upon ex vivo stimulation. Activated, but not resting, T(reg) cells in cancer tissue correlated with tumor metastases. In summary, we confirmed that activated T(reg) cells are a distinct subgroup with effector memory phenotype and fully functional regulatory activity against human colorectal cancer immunity.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907255     DOI: 10.1002/ijc.27784

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.

Authors:  Yu Jin Lim; Jaemoon Koh; Kyubo Kim; Eui Kyu Chie; Sehui Kim; Kyoung Bun Lee; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

2.  Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.

Authors:  Yingjie Nie; Jiang He; Hidekazu Shirota; Anna L Trivett; Dennis M Klinman; Joost J Oppenheim; Xin Chen
Journal:  Sci Signal       Date:  2018-01-02       Impact factor: 8.192

3.  Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.

Authors:  Suresh Gopi Kalathil; Alan Hutson; Joseph Barbi; Renuka Iyer; Yasmin Thanavala
Journal:  JCI Insight       Date:  2019-08-08

4.  Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.

Authors:  Tyler J Goodwin; Leaf Huang
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

5.  Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.

Authors:  Nicholas M Durham; Kathy Mulgrew; Kelly McGlinchey; Noel R Monks; Hong Ji; Ronald Herbst; JoAnn Suzich; Scott A Hammond; Elizabeth J Kelly
Journal:  Mol Ther       Date:  2017-06-02       Impact factor: 11.454

6.  Foxp3 expression in CD4+CD25+Foxp3+ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity.

Authors:  Xiao-Wen Zhu; Hai-Zhen Zhu; You-Qing Zhu; Mao-Hui Feng; Jian Qi; Zhi-Fen Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

7.  Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Authors:  Julie Jacobs; Vanessa Deschoolmeester; Karen Zwaenepoel; Tal Flieswasser; Christophe Deben; Jolien Van den Bossche; Christophe Hermans; Christian Rolfo; Marc Peeters; Olivier De Wever; Filip Lardon; Vasiliki Siozopoulou; Evelien Smits; Patrick Pauwels
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

Review 8.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

9.  Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells.

Authors:  Mingyang Song; Reiko Nishihara; Yin Cao; Eunyoung Chun; Zhi Rong Qian; Kosuke Mima; Kentaro Inamura; Yohei Masugi; Jonathan A Nowak; Katsuhiko Nosho; Kana Wu; Molin Wang; Edward Giovannucci; Wendy S Garrett; Charles S Fuchs; Shuji Ogino; Andrew T Chan
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777

10.  Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion.

Authors:  Li-Yuan Chang; Yung-Chang Lin; Jy-Ming Chiang; Jayashri Mahalingam; Shih-Huan Su; Ching-Tai Huang; Wei-Ting Chen; Chien-Hao Huang; Wen-Juei Jeng; Yi-Cheng Chen; Shi-Ming Lin; I-Shyan Sheen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2015-04-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.